Rosacea is a dermatologic condition affecting the centrofacial region (cheeks, chin, nose, and forehead), resulting in symptoms of facial flushing, swollen bumps on the skin surface, and a burning ...

Please provide your email address to receive an email when new articles are posted on . DFD-29 showed safety and efficacy in two phase 3 clinical rosacea trials. Significant improvements in IGA, total ...

Please provide your email address to receive an email when new articles are posted on . Journey Medical Corporation has begun the first of two phase 3 trials evaluating DFD-29 for the treatment of ...

Affecting up to 1 in 10 people worldwide, rosacea has a complex pathophysiology that remains inadequately understood, and research has hinted at multiple inflammatory and immune mediated processes ...

Epsolay is a topical cream that utilizes a patented technology process to encapsulate benzoyl peroxide 5% within silica-based microcapsules. The Food and Drug Administration (FDA) has approved Epsolay ...

SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...

Fortress Biotech announces Emrosi™ launch for rosacea, Checkpoint's acquisition by Sun Pharma, and CUTX-101 NDA acceptance for Menkes disease. Fortress Biotech, Inc. has announced a commercial launch ...

In a small, nonrandomized controlled trial, the injectable calcitonin gene-related peptide (CGRP) inhibitor erenumab significantly reduced treatment-resistant flushing and erythema associated with ...

Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea. What Happened: ...

State Medicaid formularies demonstrate significant variability in rosacea treatment coverage, with only 10% of states offering unrestricted access to basic therapeutic options, in an analysis of ...

DUBLIN, Oct. 6, 2020 /PRNewswire/ -- The "Europe Rosacea Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive ...

NEW YORK, Sept 26 (Reuters) - CollaGenex Pharmaceuticals Inc said on Wednesday it is ending development of its drug incyclinide for treating the inflammatory skin condition rosacea after a mid-stage ...